QIAGEN and Neuron23 Partner to Develop Next-Generation Sequencing Companion Diagnostic for Novel Parkinson's Disease DrugBusiness Wire • 09/14/22
Neuron23 and QIAGEN Announce Collaboration to Develop the First Next-Generation Sequencing Companion Diagnostic for Novel Parkinson's Disease DrugPRNewsWire • 09/14/22
QIAGEN Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health EmergencyBusiness Wire • 08/15/22
Qiagen NV (QGEN) CEO Thierry Bernard on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 07/29/22
QIAGEN adds new biopharma products to QIAcuity digital PCR portfolio and launches Expert Custom Assay Design ServiceBusiness Wire • 07/27/22
QIAGEN's Clinical Decision Support Platform QCI Surpasses Three Million NGS Patient Test CasesBusiness Wire • 07/19/22
Relation Therapeutics, the Active-Graph Machine Learning Drug Discovery Company, Names David Roblin as CEO and Lindsay Edwards as CTOBusiness Wire • 06/09/22
U.S. CDC Endorses the Use of Digital PCR Technology for Wastewater Surveillance of Infectious Diseases – Including COVID-19 OutbreaksBusiness Wire • 06/01/22
QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced PanelsBusiness Wire • 05/16/22
QIAGEN Adds HSV1/2 Herpes Assay With CE-IVD Certification for Use on NeuMoDx Integrated PCR SystemBusiness Wire • 05/05/22
QIAGEN N.V. (QGEN) CEO Thierry Bernard on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 04/28/22